Form 4: Zevra Therapeutics Director John B. Bode Acquires Stock Options

Director John B. Bode acquired stock options in Zevra Therapeutics as part of director compensation.

Summary

• On May 13, 2024, John B. Bode, a director of Zevra Therapeutics, Inc., was granted stock options to purchase 39,200 shares of common stock.
• The exercise price of the options is $4.89 per share, which equals the closing price of Zevra Therapeutics' common stock on the Nasdaq Global Select Market on the grant date.
• The options were granted as compensation for Bode's service on the company's board of directors, according to the Issuer's ninth amended and restated non-employee director compensation policy.
• The options vest on the earlier of (i) the first anniversary of the grant date, (ii) one day prior to the first annual meeting of the Issuer's stockholders following the grant date, or (iii) immediately prior to a change in control of the Issuer, contingent upon Bode's continued service.
• The options expire on May 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation arrangement, which is generally viewed neutrally to positively as it aligns director interests with shareholder value. There are no indications of unusual or concerning activity.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The vesting of the options is contingent upon continued service and certain events, indicating an expectation of ongoing board service from the director.

Industry Context

Granting stock options to board members is a common practice in the pharmaceutical industry to incentivize performance and align interests with shareholders. This is a standard component of director compensation packages.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also utilize stock options as part of their director compensation packages.
• The vesting schedules and exercise prices are generally structured to align with industry norms, incentivizing long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates